methods for inhibiting the activity of a cathepsin-1 protease in cells or tissue, for inhibiting overexpression of a cathepsin-1 protease in cells or tissue, and for treating a condition associated with aberrant activity and / or overexpression of a cathepsin-1 protease. cathepsin type 1 in a patient, cathepsin propeptide or a nucleic acid encoding a cathepsin propeptide, use of cathepsin propeptide or a nucleic acid encoding a cathepsin propeptide, pharmaceutical composition, and, method for recombinant production of cathepsin propeptides

摘要

METHODS FOR INHIBITING THE ACTIVITY OF A CATHYPSIN L TYPE PROTEASE IN CELLS OR TISSUE, TO INHIBIT THE OVER EXPRESSION OF A CATHYPSIN L TYPE PROTEASE IN CELLS OR TISSUE, AND TO TREAT AN ASSOCIATED CONDITION WITH OPEN AND / OR EXPERIENCE OF OVERCOMING OPERATION AND / OR OVER EXERCISE. CAThepsin L-type protease in a patient, cathepsin or a nucleic acid prototype coding a cathepsin prototype, use of cathepsin prototype or a nucleic acid, codifying a cathepine protease, making it effective in the treatment of painkillers. CATATEPSIN A method of inhibiting the activity of a cathepsin L-type protease in cells or tissue and the use of the method in the treatment of diseases such as cancer and inflammatory diseases is described. The method comprises administering a cathepsin propeptide or nucleic acid encoding a cathepsin propeptide. In particular embodiments, the propeptide is cathepsin S propeptide. In addition, the use of propeptides having an Fc moiety is described.